Close this search box.
Close this search box.

German Prostate Cancer Center

As life expectancy in the western world increases, our risk of developing prostate diseases has gone up. Almost every man nowadays is confronted with prostate disease at some stage in their life. This disease can greatly impact their quality of life and may become aggressive prostate cancer. Aggressive prostate cancer requires a team of multidisciplinary specialists to ensure the best treatment possible, and to maintain a good quality of life during and after treatment. At the GMI Prostate Cancer Center, a team of internationally acclaimed physicians guide each prostate cancer patient through their diagnostic work-up to their treatment and post-treatment care. The GMI Prostate Cancer Center will never offer a simple “one size fits all” approach to any of our patients. We create personalized treatment plans for each patient, taking their individual biological tumor characteristics, wishes and personal preferences into account.

Following our mission, “compassion drives innovation,” the GMI team runs a world renowned prostate cancer research program with the aim of transferring the most novel diagnostic and therapeutic research findings to our patients. Members of our team are leaders in prostate cancer research and care. Therefore, they participate in several international prostate cancer guideline committees and are opinion leaders in the diagnosis and treatment of prostate cancer. For more information on our ongoing trials and research programs for prostate cancer please click here.

Departments Involved

Our team

One key factor for the success of the GMI Prostate Cancer Center is our multidisciplinary approach to diagnosis and treatment. Every patient is under the care of a dedicated team of specialists that determine and implement the best treatment for each individual case. Our team consists of medical oncologists, urologists, radiologists, radiation oncologists, pathologists, and nuclear medicine physicians. Additionally, at the GMI Prostate Cancer Center our patients can meet with several specialists during a single visit.

Our services

Treatment options for each of our patients can vary greatly depending on several factors such as how advanced the condition is when diagnosed or relapsed, specific molecular tumor tissue markers and the patients’ general health. At the GMI Prostate Cancer Center the departments of Radiology, Nuclear Medicine and Pathology apply the most modern diagnostic procedures to ensure an optimal diagnostic work-up. For example, the only positron-emission tomography / computed tomography (PET/CT) scanner available in the region is at the GMI Prostate Cancer Center. It is frequently used to accurately assess the spread of the disease. For this purpose, we apply a new imaging technique called prostate-specific membrane antigen (PSMA) PET imaging. In this test, a radioactive tracer (for example the modern PSMA tracer 18F-PSMA-1007) is injected intravenously, which then attaches to PSMA proteins on the tumor cells. 

The GMI Prostate Cancer Center offers a variety of treatment options. These include high-precision radiation therapy, minimally invasive surgery, access to clinical trialshormone therapy, and chemotherapy. Specifically in the field of high-precision radiotherapy, the GMI team is a pioneer and one of the leading centers in Europe. By applying the most modern techniques such as high-dose rate brachytherapy or stereotactic-body radiotherapy, the prostate and the intraprostatic cancer mass can be treated with millimeter accuracy. Through these treatments, the adjacent organs like the rectum and the bladder are spared. A novel treatment option for patients with more advanced stages of the disease is the so called PSMA radioligand therapy. To determine the best possible cancer treatment and care plan, our multidisciplinary team of experts meet weekly at the GMI urologic malignancies tumor board.

Self-Help and Patient Advocacy

For our patients and their loved ones, the diagnosis of cancer or another severe disease can come as a shock. Feelings like confusion, anxiety and loneliness may come up, even if family or friends are there to help. These feelings are all part of the process of coping with a new and stressful situation. Becoming more knowledgeable about prostate cancer and aware of the available treatment options can help you handle these feelings and make informed decisions. Additionally, the process of taking charge of your treatment can be empowering. 

Our dedicated patient support teams help both the patients and their loved ones during their entire prostate cancer journey, from their first arrival at the GMI to after their treatment. Support groups, social and psychological support and patient advocacy can help you with decision-making, can improve your overall quality of life and can possibly even contribute to prolonging your life. For example, the opportunity to talk to other men whose prostate cancer was successfully treated can be tremendously reassuring. The same benefits exist when talking to men whose initial treatment had failed or who have dealt with a recurrence of their prostate cancer.

Prostate cancer patient support resources include the following:

  • The GMI Patient Advocacy Liaison Service (PALS) offers its services to both patients and loved ones: confidential advice, support and information on prostate cancer-related matters.
  • Local prostate cancer patient representative groups like EuropaUomo and Movember organize special events, classes and patient support groups.

The GMI Clinical Psychology Program offers psychological support to our patients and their relatives. Emphasis is given to self-help mechanisms.

Contact details

24-hour Emergency Helpline

(+357) 25 208 000

Emergencies are not yet accredited of the General Health Care System

(+357) 25 208 000

Emergencies are not yet accredited of the General Health Care System.


Dr. Aris Angouridis

About me:

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.